SCHEMBL5779320

SCHEMBL5779320

C=C(F)[Si](C)(C)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
NR1H2 P55055 3/20 0.38
NR1H3 Q13133 3/20 0.38
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.36
CES2 O00748 2/20 0.34
CES1 P23141 2/20 0.34
LMNA P02545 1/20 0.33
XBP1 P17861 1/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ACHE P22303 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2004840 0.81 ESR1 (0.41) ESR1ESR2NR1H2NR1H3MAPT
SCHEMBL7900984 0.78 ESR1 (0.43) ESR1ESR2NR1H2NR1H3MAPT
SCHEMBL10707272 0.76 ESR1 (0.41) ESR1ESR2NR1H2NR1H3MAPT
SCHEMBL16706156 0.75 ESR1 (0.44) ESR1ESR2NR1H2NR1H3MAPT
SCHEMBL6874393 0.75 ESR1 (0.50) ESR1ESR2NR1H2NR1H3MAPT
SCHEMBL27565431 0.73 ESR1 (0.48) ESR1ESR2MAPTHPGDCES2
SCHEMBL552036 0.73 ESR1 (0.39) ESR1ESR2NR1H2NR1H3MAPT
SCHEMBL5364559 0.71 MAPT (0.42) ESR1ESR2MAPTHPGDCES2
SCHEMBL9223978 0.71 SMN1; SMN2 (0.41) ESR1ESR2MAPTHPGDSMN1; SMN2
SCHEMBL28532520 0.71 ACHE (0.44) ESR1ESR2NR1H2NR1H3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741897-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2014-06-03 US disclosed
US-8741897-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2014-06-03 US disclosed
EP-1673088-A1 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-06-28 EP disclosed
US-20050176706-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-11 US disclosed
WO-2005030213-A1 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176706-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof NR3C1, NR3C2, MC2R ESR1 323/4885ESR2 620/4885NR1H2 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.